Natural Product (NP) Details

General Information of the NP (ID: NP2169)
Name
Vitamin K
Synonyms
VITAMIN K; Kinadion; Konakion; Mephyton; Monodion; Kephton; Aqua mephyton; Synthex P; Mono-Kay; Combinal K1; Kativ N; K-Ject; 12001-79-5; Aquamephyton; Phythyl-menadion; 2',3'-trans-Vitamin K1; Aqua-Mephytin; Vitamin K1(20); .alpha.-Phylloquinone; trans-Phylloquinone; Phytomenadionum; 2-methyl-3-[(E)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione; 2-Methyl-3-phythyl-1,4-naphthochinon; 81818-54-4; Fitomenadione; 2-methyl-3-[(2E)-3,7,11,15-tetramethylhexadec-2-en-1-yl]-1,4-dihydronaphthalene-1,4-dione; 3-((2E)-3,7,11,15-tetramethylhexadec-2-enyl)-2-methylnaphthalene-1,4-dione; SMR000059144; Vitamin K semiquinone radical; a-Phylloquinone; NSC-270681; 2-methyl-3-[(2E)-3,7,11,15-tetramethylhexadec-2-en-1-yl]naphthalene-1,4-dione; NCGC00159423-02; Mephyton (TN); EINECS 234-408-7; EINECS 279-833-9; Vitamin K (generic); Phytomenadione (INN); Vitamin K1 (TN); 2-methyl-3-(3,7,11,15-tetramethylhexadec-2-en-1-yl)naphthalene-1,4-dione; Vitamin K1 (Phytonadione); Phytonadione (JP17/USP); MLS001332659; MLS001332660; CHEMBL520156; 2-Methyl-3-[(2E)-3,7,11,15-tetramethyl-2-hexadecenyl]naphthoquinone #; CHEBI:94399; [r-[r*,R*-(E)]]-2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-napthalenedione; [r-[r*,R*-(E)]]-2-Methyl-3-(3-7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione; HMS2232C17; 10485-69-5; BCP23822; BBL036678; NSC270681; STL559057; 2-Methyl-3-(3,7,11,15-tetramethylhexadec-2-enyl)-1,4-naphthoquinone; 2-Methyl-3-phytyl-1,4-napthoquinone; AKOS024284357; NCGC00186656-01; 27696-10-2; ST075162; VS-13623; P0642; C02059; D00148; 1, 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-; 2-(3,7,11,15-Tetramethyl-2-hexadecenyl)-3-methyl-1,4-naphthoquinone; 2-(3,7,11,15-Tetramethylhexadec-2-enyl)-3-methylnaphthalene-1,4-dione; 2-Methyl-3-(3,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione; (E)-2-Methyl-3-(3,7,11,15-tetramethylhexadec-2-en-1-yl)naphthalene-1,4-dione1; 1, 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-, [R-[R*,R*-(E)]]-; 2-Methyl-3-[(2Z)-3,7,11,15-tetramethyl-2-hexadecenyl]-1,4-naphthoquinone; 1,4-Naphthalenedione, 2-methyl-3-((2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecenyl)-, radical ion(1-); 1,4-Naphthalenedione, 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-, radical ion(1-), (R-(R*,R*-(E)))-; 2581046-19-5
    Click to Show/Hide
Species Origin Medicago sativa ...     Click to Show/Hide
Medicago sativa
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Fabales
Family: Fabaceae
Genus: Medicago
Species: Medicago sativa
Disease Breast cancer [ICD-11: 2C60] Investigative [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absporption
Caco-2 Permeability
 -4.998
 
MDCK Permeability
 -4.784
 
PAMPA
 - - -
 
HIA
 - - -
 
Distribution
VDss
 0.405
 
PPB
 98.6%
 
BBB
 - - -
 
Metabolism
CYP1A2 inhibitor
 ++
CYP1A2 substrate
 - -
CYP2C19 inhibitor
 +++
CYP2C19 substrate
 +++
CYP2C9 inhibitor
 +++
CYP2C9 substrate
 - -
CYP2D6 inhibitor
 +++
CYP2D6 substrate
 - - -
CYP3A4 inhibitor
 -
CYP3A4 substrate
 - - -
CYP2B6 inhibitor
 +++
CYP2B6 substrate
 - - -
CYP2C8 inhibitor
 +++
HLM Stability
 +++
 
Excretion
CLplasma
 6.305
 
T1/2
 0.352
Toxicity
DILI
 - -
 
Rat Oral Acute Toxicity
 - -
 
FDAMDD
 -
 
Respiratory
 ++
 
Human Hepatotoxicity
 ++
 
Ototoxicity
 +
 
Drug-induced Nephrotoxicity
 -
 
Drug-induced Neurotoxicity
 - -
 
Hematotoxicity
 +
 
Genotoxicity
 - - -
 
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++). 2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C31H46O2
PubChem CID
5280483
Canonical SMILES
CC1=C(C(=O)C2=CC=CC=C2C1=O)CC=C(C)CCCC(C)CCCC(C)CCCC(C)C
InChI
1S/C31H46O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,18-20,22-24H,9-17,21H2,1-6H3/b25-20+
InChIKey
MBWXNTAXLNYFJB-LKUDQCMESA-N
CAS Number
CAS 12001-79-5
ChEBI ID
CHEBI:94399
Herb ID
HBIN048067
SymMap ID
SMIT18325
TTD Drug ID
D07QPA
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Sorafenib      Renal cell carcinoma     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Up-regulation Expression CDH1  Molecule Info 
Pathway MAP
Up-regulation Phosphorylation ERK1  Molecule Info 
Pathway MAP
Up-regulation Expression HGFAC  Molecule Info 
Pathway MAP
Up-regulation Expression MET  Molecule Info 
Pathway MAP
                    In-vitro Model Hep-G2 CVCL_0027 Hepatocellular carcinoma Homo sapiens
                    Experimental
                    Result(s)		 Sorafenib and vitamin K can function synergistically to inhibit the migration and proliferation of HCC cells.
Target and Pathway
Target(s) Coagulation factor IIa (F2)  Molecule Info  [3]
KEGG Pathway Neuroactive ligand-receptor interaction Click to Show/Hide
2 Complement and coagulation cascades
3 Regulation of actin cytoskeleton
NetPath Pathway TCR Signaling Pathway Click to Show/Hide
Panther Pathway Blood coagulation Click to Show/Hide
Pathwhiz Pathway Vitamin K Metabolism Click to Show/Hide
2 Coagulation
Pathway Interaction Database Thrombin/protease-activated receptor (PAR) pathway Click to Show/Hide
2 Angiopoietin receptor Tie2-mediated signaling
3 FOXA2 and FOXA3 transcription factor networks
4 PAR4-mediated thrombin signaling events
5 Syndecan-4-mediated signaling events
6 PAR1-mediated thrombin signaling events
Reactome Intrinsic Pathway of Fibrin Clot Formation Click to Show/Hide
2 Common Pathway of Fibrin Clot Formation
3 Gamma-carboxylation of protein precursors
4 Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus
5 Removal of aminoterminal propeptides from gamma-carboxylated proteins
6 Cell surface interactions at the vascular wall
7 Peptide ligand-binding receptors
8 Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
9 G alpha (q) signalling events
10 Thrombin signalling through proteinase activated receptors (PARs)
WikiPathways Complement and Coagulation Cascades Click to Show/Hide
2 Regulation of Actin Cytoskeleton
3 IL1 and megakaryotyces in obesity
4 Regulation of Insulin-like Growth Factor (IGF) Transport and Uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
5 PTM: gamma carboxylation, hypusine formation and arylsulfatase activation
6 Blood Clotting Cascade
7 Gastrin-CREB signalling pathway via PKC and MAPK
8 Thrombin signalling through proteinase activated receptors (PARs)
9 Platelet Aggregation (Plug Formation)
10 GPCR ligand binding
11 GPCR downstream signaling
12 Formation of Fibrin Clot (Clotting Cascade)
13 Cell surface interactions at the vascular wall
14 Folate Metabolism
15 Vitamin B12 Metabolism
16 Selenium Micronutrient Network
References
Reference 1 Vitamin K 2 induces non-apoptotic cell death along with autophagosome formation in breast cancer cell lines. Breast Cancer. 2020 Mar;27(2):225-235.
Reference 2 Synergistic effect of sorafenib and vitamin K on suppression of hepatocellular carcinoma cell migration and metastasis. Anticancer Res. 2015 Apr;35(4):1985-95.
Reference 3 Plasma levels of protein C and vitamin K-dependent coagulation factors in patients on long-term oral anticoagulant therapy. Tohoku J Exp Med. 1986 Aug;149(4):351-7.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link